SGLT2 inhibitors and diabetic retinopathy progression.
Jennifer B NadelmannCharles G MillerBrendan McGeehanYinxi YuBrian L VanderBeekPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2023)
Exposure to SGLT2 inhibitor therapy was not associated with progression of NPDR compared to patients receiving other diabetic therapies.